Scholar Rock Holding Corp. (NASDAQ: SRRK) is a biotech firm focusing on neuromuscular disease treatment. Despite a 33% YTD drop, solid Phase 3 data for drug apitegromab suggests regulatory approval potential in 2026. Analysts predict a Buy rating with over 65% upside potential.

Globant (NYSE: GLOB), a tech services firm, has seen a 70% YTD decline due to a middling second quarter. The upcoming earnings report will be crucial in converting AI demand into revenue. Analysts are cautious, but a small win could lead to a significant stock rally.

NiCE Ltd. (NASDAQ: NICE) has strengthened its cloud and AI offerings, boosting annual recurring revenue. With the acquisition of Cognigy, revenue growth of 7% YOY is expected. Despite a 25% YTD fall, optimism is growing among retail investors and analysts predict a 57% upside potential. Watch for broad fundamental improvement in the upcoming earnings report.

Read more at Nasdaq: 3 Beaten-Down Stocks With Rebound Potential This Earnings Season